Leveraging advances in mRNA and nanotechnology, researchers demonstrate that tumor suppressor PTEN can be restored in preclinical models of prostate cancer.
Leveraging advances in mRNA and nanotechnology, researchers demonstrate that tumor suppressor PTEN can be restored in preclinical models of prostate cancer.